## STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 168-5 (GENERAL MEDICINES)

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status			
1	9M INDIA LIMITED	Technical Evalua	echnical Evaluation Remarks by Committee of DCA: Submitted all documents may be considered with S.No. 1 to 19 items					
	1	1733	Adenosine Injection IP 3mg / ml 2ml vial or ampoule		May be considered			
	2	1477	Azithromycin Tablets IP 500 mg		May be considered			
	3	140224006	Betoxolol Eye Drops 0.5 percentage		May be considered			
	4	2146	Carbimazole Tablets 20mg		May be considered			
	5	1218	Dobutamine Hcl For Injection USP 250mg / 20 ml Vial		May be considered			
	6	1462	Ethamsylate Injection 125mg/ml 2 ml ampoule		May be considered			
	7	266	Furosemide Injection, IP 10mg/1ml in 2 ml amp		May be considered			
	8	265	Furosemide Tablets IP 40mg		May be considered			
	9	140224099	Hydrocortisone acetate 10 percentage w/w oint 20.8 gm		May be considered			
	10	140224137	Inj L ornithine L apartate 5g/10ml		May be considered			
	11	140224025	Inj Lidocaine 2 percentage preservative free 50 ml multi dose vial		May be considered			
	12	140224027	Inj Phenylephrine 2ml		May be considered			
	13	2319	Ketorolac Tromethamine Injection 30mg /ml, 1 ml Ampoule		May be considered			
	14	1694	Labetalol Hcl Injection IP 5mg / ml in 10ml vial		May be considered			
	15	1442	Mephentramine Sulphate Injection 30 mg /ml in 10 ml vial		May be considered			
	16	1903	Olanzapine Tablets 5 mg		May be considered			
	17	752	Phenytoin Sodium Injection IP 50mg/ml in 5ml vial		May be considered			
	18	140224063	Sodium phosphate 10 gm Enema pack 100ML		May be considered			
	19	2087.01	Tab.Entecavir 1mg		May be considered			
2	alkem laboratories ltd	Technical Evalua	tion Remarks by Committee of DCA: May b	e considered with items of S.No. 1 to 3				
	1	1477	Azithromycin Tablets IP 500 mg		May be considered			
	2	1622	Cefixime Tablets IP 200 mg		May be considered			
	3	1903	Olanzapine Tablets 5 mg		May be considered			
3	Apple Formulations Private Limited	Technical Evalua	tion Remarks by Committee of DCA: The fin	rm and the two products may be considered				
	1	1477	Azithromycin Tablets IP 500 mg		May be considered			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	265	Furosemide Tablets IP 40mg		May be considered
4	Bharat Serums And Vaccines Ltd	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm may be considered after submission of valid <b>Retention certificate</b>	
	1	632	Antisnake Venom Injection	Not submitted valid <b>product Retention certificate</b> May be considered after submission of valid retention certificate	May not be considered
5	Biological E. Limited	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm and the product may be considered	
	1	632	Antisnake Venom Injection		May be considered
6	Centaur Pharmaceuticals Private Limited	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm may be considered after submission of <b>valid product approval</b>	
	1	140224052	Papain IP 521700 Units, Urea IP 100mg Ointment per each gram, 15gms tube	The composition or strength not mentioned in the product approval	May not be considered
7	CIPCO PHARMACEUTICALS	Technical Evaluat	ion Remarks by Committee of DCA: All th	e necessary documents submitted by the applicant, Hence S.No. 1 may be considered as pe	er tender conditions
	1	1477	Azithromycin Tablets IP 500 mg		May be considered
8	CMG BIOTECH PVT LTD	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm with 6 products may be considered after submission of <b>valid GMP certificate</b> of mfg co	ompany
	1	1477	Azithromycin Tablets IP 500 mg		May be considered
	2	2281	Escitalopram Tablets 5mg		May be considered
	3	265	Furosemide Tablets IP 40mg		May be considered
	4	1903	Olanzapine Tablets 5 mg		May be considered
	5	2397	Quetiapine 25mg Tablet		May be considered
	6	2087.01	Tab.Entecavir 1mg		May be considered
9	Concord Drugs	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm may be considered with S.No. 1 to 7 products	
	1	7	Amoxicillin Capsules IP 500 mg		May be considered
	2	1477	Azithromycin Tablets IP 500 mg		May be considered
	3	1622	Cefixime Tablets IP 200 mg		May be considered
	4	2281	Escitalopram Tablets 5mg		May be considered
	5	1903	Olanzapine Tablets 5 mg		May be considered
	6	2126	Pregabalin SR Tablet 75mg		May be considered
	7	2397	Quetiapine 25mg Tablet		May be considered
10	Eurokem Laboratories Pvt Ltd.	Technical Evaluat	• • •	rm may be considered after submission of <b>valid product license</b>	

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	265	Furosemide Tablets IP 40mg	Not submitted <b>valid product license</b> May be considered after submission of valid product license	May not be considered
	2	2313	Isosorbide Dinitrate Tablets 10mg	Not submitted <b>valid product license</b> May be considered after submission of valid product license	May not be considered
	FRESENIUS KABI ONCOLOGY LIMITED	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with S.No. 1 to 2 products	
	1	2234	Carboplatin 450mg / 45 ml Injection Vial		May be considered
	2	1907	Paclitaxel Injection IP 30 mg / 5 ml		May be considered
12	G K HEALTHCARE	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered after submission of <b>valid NCC</b>	
	1	1622	Cefixime Tablets IP 200 mg		May be considered
13	HEALERS LAB	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	1477	Azithromycin Tablets IP 500 mg		May be considered
14	Imaging Products India Pvt Ltd	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered after submission of <b>valid product license</b>	
	1	140224109	Non ionic contrast gadotridol 0.5M 10ml/15ml	Not submitted <b>valid product license</b> May be considered after submission of valid product license	May not be considered
	2	140224104	Non ionic contrast Iomeprol 400mg 50ml/100ml	Not submitted <b>valid product license</b> May be considered after submission of valid product license	May not be considered
	3	140224106	Oral contrast Sodium diatrizoate 25 percentage 30ml/100ml	Not submitted <b>valid product license</b> May be considered after submission of valid product license	May not be considered
15	J.P. INDUSTRIES		tion Remarks by Committee of DCA: Applie ay be considered after submission of correct	cant submitted all the documents S.No. 1, 2, 3, 4, 5, 6 & 8 may be considered <b>t product approval</b>	
	1	1477	Azithromycin Tablets IP 500 mg		May be considered
	2	2223	Calciferol Oral Drops 75 mcg/ml 20 ml		May be considered
	3	2231	Carbimazole Tablet 10mg		May be considered
	4	2146	Carbimazole Tablets 20mg		May be considered
	5	265	Furosemide Tablets IP 40mg		May be considered
	6	1903	Olanzapine Tablets 5 mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	7	2126	Pregabalin SR Tablet 75mg	Not submitted product approval for <b>tablets</b> (submitted approval for capsules at S.No. 6 of pg no14) May be considered after submission of correct product approval	May not be considered
	8	2397	Quetiapine 25mg Tablet		May be considered
16	KONIS PHARMACEUTICALS	Technical Evalua	ation Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	266	Furosemide Injection , IP 10mg/1ml in 2 ml amp		May be considered
	2	2319	Ketorolac Tromethamine Injection 30mg /ml, 1 ml Ampoule		May be considered
17	LEOSTAR HEALTHCARE PRIVATE LIMITED	Technical Evalua	ation Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	7	Amoxicillin Capsules IP 500 mg		May be considered
	2	1477	Azithromycin Tablets IP 500 mg		May be considered
	3	1622	Cefixime Tablets IP 200 mg		May be considered
18	MALIK LIFESCIENCES PRIVATE LIMITED	Technical Evalua	ation Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	7	Amoxicillin Capsules IP 500 mg		May be considered
	2	1622	Cefixime Tablets IP 200 mg		May be considered
19	MARC LABORATORIES LTD	Technical Evalua	ation Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	7	Amoxicillin Capsules IP 500 mg		May be considered
	2	1622	Cefixime Tablets IP 200 mg		May be considered
20	MICRON PHARMACEUTICALS	Technical Evalua	ation Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	7	Amoxicillin Capsules IP 500 mg		May be considered
	2	1477	Azithromycin Tablets IP 500 mg		May be considered
	3	1622	Cefixime Tablets IP 200 mg		May be considered
21	Modern Laboratories	Technical Evalua	ation Remarks by Committee of DCA: The fi	rm may be considered with applied products	
	1	7	Amoxicillin Capsules IP 500 mg		May be considered
	2	1477	Azithromycin Tablets IP 500 mg		May be considered
	3	1622	Cefixime Tablets IP 200 mg		May be considered
	4	266	Furosemide Injection , IP 10mg/1ml in 2 ml amp		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status		
	5	265	Furosemide Tablets IP 40mg		May be considered		
	6	140224116	Tab.Feropenam 200mg		May be considered		
22	NESTOR PHARMACEUTICALS LIMITED	Technical Evalua	echnical Evaluation Remarks by Committee of DCA: The firm may be considered with applied products				
	1	7	Amoxicillin Capsules IP 500 mg		May be considered		
	2	1477	Azithromycin Tablets IP 500 mg		May be considered		
	3	1622	Cefixime Tablets IP 200 mg		May be considered		
	4	266	Furosemide Injection , IP 10mg/1ml in 2 ml amp		May be considered		
	5	2313	Isosorbide Dinitrate Tablets 10mg		May be considered		
23	PURE AND CURE HEALTHCARE PRIVATE LIMITED	Technical Evalua	tion Remarks by Committee of DCA: The f	irm may be considered with applied products			
	1	1477	Azithromycin Tablets IP 500 mg		May be considered		
	2	2126	Pregabalin SR Tablet 75mg		May be considered		
24	RAY LIFE SCIENCES PVT LTD		tion Remarks by Committee of DCA: The f d product approval	irm may be considered after submission of product list acknowledged by Licensing authority	y along with <b>Retention</b>		
	1	1733	Adenosine Injection IP 3mg / ml 2ml vial or ampoule	Submitted at pg no 19, Not submitted product list acknowledged by Licensing authority along with Retention May be considered after submission of <b>valid product approval</b>	May not be considered		
	2	1462	Ethamsylate Injection 125mg/ml 2 ml ampoule	Submitted approval for <b>Export purpose only</b>	May not be considered		
	3	266	Furosemide Injection , IP 10mg/1ml in 2 ml amp	Submitted document valid upto 02.04.2024 May be considered after submission of <b>valid product approval</b>	May not be considered		
	4	2319	Ketorolac Tromethamine Injection 30mg /ml, 1 ml Ampoule	Submitted at pg no 16, Not submitted product list acknowledged by Licensing authority along with Retention May be considered after submission of <b>valid product approval</b>	May not be considered		
	5	1901	Octreotide Injection 100mcg/ml	Not submitted May be considered after submission of <b>valid product approval</b>	May not be considered		
25	SAI PARENTERALS LIMITED	Technical Evalua	Technical Evaluation Remarks by Committee of DCA: The firm may be considered with applied products				
	1	1477	Azithromycin Tablets IP 500 mg		May be considered		
	2	1622	Cefixime Tablets IP 200 mg		May be considered		

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status		
26	SAMARTH LIFE SCIENCES PRIVATE LIMITED	Technical Evalua	Technical Evaluation Remarks by Committee of DCA: The firm may be considered with applied products				
	1	1733	Adenosine Injection IP 3mg / ml 2ml vial or ampoule		May be considered		
	2	1218	Dobutamine Hcl For Injection USP 250mg / 20 ml Vial		May be considered		
	3	140224137	Inj L ornithine L apartate 5g/10ml		May be considered		
	4	1897	Nitroglycerine (N.T.G.) Injection 5mg/ml in 5 ml		May be considered		
	5	1901	Octreotide Injection 100mcg/ml		May be considered		
	6	1907	Paclitaxel Injection IP 30 mg / 5 ml		May be considered		
27	SAMKEM	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with applied products			
	1	1477	Azithromycin Tablets IP 500 mg		May be considered		
	2	2460	Canagliflozin Tablet 100mg		May be considered		
	3	2231	Carbimazole Tablet 10mg		May be considered		
	4	2281	Escitalopram Tablets 5mg		May be considered		
	5	2090	Fluconazole For Oral suspension 50mg per 5ml (Pack Size 35ml)		May be considered		
	6	265	Furosemide Tablets IP 40mg		May be considered		
	7	1874	Methotrexate Tablets IP 2.5 mg		May be considered		
	8	1903	Olanzapine Tablets 5 mg		May be considered		
	9	140224052	Papain IP 521700 Units, Urea IP 100mg Ointment 1 percentage W/W, 100gms tube		May be considered		
	10	2126	Pregabalin SR Tablet 75mg		May be considered		
	11	140224003	Tab.Azathioprine 100mg		May be considered		
	12	2087.01	Tab.Entecavir 1mg		May be considered		
	13	13122313	Tab.Pentoxiphylline 400mg		May be considered		
	14	13122312	Tab.Propylthiouracil 50 mg		May be considered		
28	SEEKO BIOTICS	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with applied products			
	1	7	Amoxicillin Capsules IP 500 mg		May be considered		
	2	1477	Azithromycin Tablets IP 500 mg		May be considered		
	3	2146	Carbimazole Tablets 20mg		May be considered		
	4	1622	Cefixime Tablets IP 200 mg		May be considered		
	5	2281	Escitalopram Tablets 5mg		May be considered		
	6	265	Furosemide Tablets IP 40mg		May be considered		
	7	2313	Isosorbide Dinitrate Tablets 10mg		May be considered		
	8	1903	Olanzapine Tablets 5 mg		May be considered		
	9	2126	Pregabalin SR Tablet 75mg		May be considered		

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status	
	10	2397	Quetiapine 25mg Tablet		May be considered	
29	SIGNATURE PHYTOCHEMICAL INDUSTRIES	Technical Evaluation Remarks by Committee of DCA: The firm may not be considered, firm may be considered after submission of valid product license				
	1	7	Amoxicillin Capsules IP 500 mg	May be considered after submission of valid product <b>approval acknowledge by the</b> <b>Licensing authority for this current licensing period</b>	May not be considered	
	2	1477	Azithromycin Tablets IP 500 mg	May be considered after submission of valid product <b>approval acknowledge by the</b> Licensing authority for this current licensing period	May not be considered	
	3	1622	Cefixime Tablets IP 200 mg	May be considered after submission of valid product <b>approval acknowledge by the</b> Licensing authority for this current licensing period	May not be considered	
30	STRIDE ORGANICS PVT LTD	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with applied products		
	1	1477	Azithromycin Tablets IP 500 mg		May be considered	
	2	1622	Cefixime Tablets IP 200 mg		May be considered	
	3	140224062	Soda lime crystals 5kg tins		May be considered	
31	SUZIKEM DRUGS PRIVATE LIMITED	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with applied product		
	1	1477	Azithromycin Tablets IP 500 mg		May be considered	
32	SYNMEDIC LABORATORIES	Technical Evalua	tion Remarks by Committee of DCA: The fi	rm may be considered with applied product		
	1	265	Furosemide Tablets IP 40mg		May be considered	
33	TALENT HEALTHCARE	authority for curr		cant not submitted the <b>valid Non Conviction Certificate &amp; product approval</b> for S.No. 1 cant, Hence S.No.1 to 7 products may be considered after submission of <b>valid Non Convic</b>		
	1	7	Amoxicillin Capsules IP 500 mg		May be considered	
	2	1477	Azithromycin Tablets IP 500 mg	Submitted at s.no. 12 of pg no12 May be considered after submission of <b>latest product approval</b>	May not be considered	
	3	1622	Cefixime Tablets IP 200 mg		May be considered	
	4	2281	Escitalopram Tablets 5mg		May be considered	
	5	1874	Methotrexate Tablets IP 2.5 mg		May be considered	
	6	1903	Olanzapine Tablets 5 mg		May be considered	
	7	2397	Quetiapine 25mg Tablet		May be considered	
34	THERDOSE PHARMA PRIVATE LIMITED	Technical Evalua	echnical Evaluation Remarks by Committee of DCA: S.No. 1 & 2 products may be considered after submission of valid Non Conviciton Certificate			
	1	2234	Carboplatin 450mg / 45 ml Injection Vial		May be considered	

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status			
	2	1907	Paclitaxel Injection IP 30 mg / 5 ml		May be considered			
35	Troikaa Pharmaceuticals Limited	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm may be considered with applied products				
	1	140224012	Inj.Etomidate 2 mg /ml, 20mg/10 ml Vial		May be considered			
	2	1442	Mephentramine Sulphate Injection 30 mg /ml in 10 ml vial		May be considered			
36	Unicure India Pvt. Ltd.	Technical Evaluat product approval	ion Remarks by Committee of DCA: The fi	rm may not be considered, Firm may be considered after submission <b>of Non Conviction C</b>	ertificate and valid			
	1	7	Amoxicillin Capsules IP 500 mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	2	1477	Azithromycin Tablets IP 500 mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	3	1622	Cefixime Tablets IP 200 mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	4	265	Furosemide Tablets IP 40mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	5	2313	Isosorbide Dinitrate Tablets 10mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	6	1903	Olanzapine Tablets 5 mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	7	2397	Quetiapine 25mg Tablet	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
	8	13122313	Tab.Pentoxiphylline 400mg	May be considerd after submission of valid product approval acknowledged by the <b>Licensing authority for this current licensing period</b>	May not be considered			
37	vins bio products limited	Technical Evaluat	Technical Evaluation Remarks by Committee of DCA: The firm may be considered with applied product					
	1	632	Antisnake Venom Injection		May be considered			
38	WILCURE REMEDIES PRIVATE LIMITED		Technical Evaluation Remarks by Committee of DCA: S.No. 1 & 2 products may be considered after submission of product approval of current licensing period attested by Licencing authority					
	1	7	Amoxicillin Capsules IP 500 mg	Submitted at S.No. 6 at pg no.10 May be considered after submission of product approval of <b>current licensing period</b>	May not be considered			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status			
	2	1477		Submitted at S.No. 6 at pg no.10 May be considered after submission of product approval of <b>current licensing period</b>	May not be considered			
39	YELURI FORMULATIONS PVT. LTD.	Technical Evaluat	echnical Evaluation Remarks by Committee of DCA: The firm may be considered with applied product					
	1	7	Amoxicillin Capsules IP 500 mg		May be considered			
40	ZEST PHARM	Technical Evaluat	ion Remarks by Committee of DCA: The fi	rm may be considered with applied products				
	1	7	Amoxicillin Capsules IP 500 mg		May be considered			
	2	1477	Azithromycin Tablets IP 500 mg		May be considered			
	3	1622	Cefixime Tablets IP 200 mg		May be considered			
	Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PM on 09.07.2025 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 168-5 (General Medicines) TEC Report							